SCHEMBL6571783

SCHEMBL6571783

Cc1cccc(S(=O)(=O)Nc2ccc(C)c(NC(=O)Cc3ccc(C#N)cc3)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 3/20 0.46
HPGD P15428 1/20 0.46
RORC P51449 3/20 0.44
MGAT2 Q10469 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PKM P14618 1/20 0.43
KDM1A O60341 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 2/20 0.43
ATIC P31939 1/20 0.43
MAPK1 P28482 1/20 0.43
IDO1 P14902 1/20 0.43
HIF1A Q16665 1/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
IDH1 O75874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766536 0.91 HDAC1 (0.52) LMNAMAPTHPGDRORCMGAT2
SCHEMBL6765129 0.85 MGAT2 (0.56) LMNAALDH1A1HPGDRORCMGAT2
SCHEMBL6765892 0.84 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MAPTHPGDMGAT2
SCHEMBL6762133 0.83 POLB (0.53) LMNAALDH1A1HPGDRORCPKM
SCHEMBL6574325 0.83 LMNA (0.44) LMNAALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL6766083 0.80 HDAC1 (0.51) LMNARORCKDM1AATICIDO1
SCHEMBL6571948 0.80 HDAC1 (0.48) LMNAALDH1A1HPGDRORCPKM
SCHEMBL6574056 0.80 RORC (0.45) LMNAALDH1A1HPGDRORCMGAT2
SCHEMBL6569935 0.79 MCL1 (0.49) LMNAALDH1A1MAPTHPGDRORC
SCHEMBL6574032 0.78 HIF1A (0.43) LMNAALDH1A1MAPTHPGDRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-12-09 US disclosed
EP-1414790-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-05-06 EP disclosed
WO-2003000653-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions NAT1, CYP3A5, CYP3A7 LMNA 1447/4885ALDH1A1 669/4885SMN1; SMN2 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.